文献速递肾移植

肾移植中的衰弱:测量、管理与未来考量综述

An overview of frailty in kidney transplantation: measurement, management and future considerations.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

本文综述衰弱在肾移植前及移植后人群中的研究应用。衰弱是一种老年学概念,用于识别面对健康压力源时脆弱性增加的老年人。肾移植是终末期肾病的优选治疗,但移植前候选者常需克服终末期肾病相关的健康挑战,移植后手术和免疫抑制又构成额外压力。衰弱指标可帮助识别移植候选者和受者中不良结局风险较高者及可能从干预中获益者。

要点

  • 身体衰弱表型是终末期肾病研究中最常用的衰弱指标。
  • 移植时衰弱的肾移植受者(约20%)死亡风险是非衰弱受者的两倍。
  • 衰弱是移植后不良结局的独立危险因素,但未纳入现行移植项目风险调整方程。

核心结论

  • 衰弱是肾移植后不良结局的独立危险因素,但当前未纳入移植项目风险调整方程。
  • 需要疾病特异性衰弱指标来监测肾移植候选者和受者。
  • 未来需研究移植前和移植后干预以改善或预防衰弱。

研究设计与样本

  • 本文为综述,汇总了衰弱应用于肾移植前和移植后人群的研究。

主要发现

  • 移植时衰弱的肾移植受者(约20%的受者)死亡风险是非衰弱受者的两倍。
  • 身体衰弱表型是终末期肾病研究中最常用的衰弱指标。
  • 研究和临床实践中还使用许多其他指标评估移植前和移植后脆弱性。

关键数值与推荐

  • 身体衰弱表型是终末期肾病研究中最常用的衰弱指标。
  • 移植时衰弱的肾移植受者约占20%,其死亡风险为非衰弱受者的两倍。

临床怎么用

  • 衰弱指标可用于识别肾移植候选者和受者中不良健康结局风险较高者。
  • 衰弱指标有助于识别可能从改善衰弱状态的干预中获益者。

局限性

  • 需要疾病特异性衰弱指标来监测肾移植候选者和受者。
  • 衰弱未纳入当前移植项目风险调整方程。
  • 未来需研究移植前和移植后干预以改善或预防衰弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The construct of frailty was first developed in gerontology to help identify older adults with increased vulnerability when confronted with a health stressor. This article is a review of studies in which frailty has been applied to pre- and post-kidney transplantation (KT) populations. Although KT is the optimal treatment for end-stage kidney disease (ESKD), KT candidates often must overcome numerous health challenges associated with ESKD before receiving KT. After KT, the impacts of surgery and immunosuppression represent additional health stressors that disproportionately impact individuals with frailty. Frailty metrics could improve the ability to identify KT candidates and recipients at risk for adverse health outcomes and those who could potentially benefit from interventions to improve their frail status. The Physical Frailty Phenotype (PFP) is the most commonly used frailty metric in ESKD research, and KT recipients who are frail at KT (~20% of recipients) are twice as likely to die as nonfrail recipients. In addition to the PFP, many other metrics are currently used to assess pre- and post-KT vulnerability in research and clinical practice, underscoring the need for a disease-specific frailty metric that can be used to monitor KT candidates and recipients. Although frailty is an independent risk factor for post-transplant adverse outcomes, it is not factored into the current transplant program risk-adjustment equations. Future studies are needed to explore pre- and post-KT interventions to improve or prevent frailty.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Harhay MN, Rao MK, Woodside KJ, et al. An overview of frailty in kidney transplantation: measurement, management and future considerations. Nephrol Dial Transplant. 2020. PMID: 32191296. doi:10.1093/ndt/gfaa016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。